Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.49 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 12/20 | 0.41 |
| ▸ | MGAM | O43451 | 11/20 | 0.41 |
| ▸ | AMY1A | P0DUB6 | 11/20 | 0.41 |
| ▸ | SI | P14410 | 11/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 11/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.41 |
| ▸ | F12 | P00748 | 2/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598295 | 0.82 | GLA (0.38) | DGAT1KCNMA1GAAMGAMAMY1A | |
| SCHEMBL1971917 | 0.75 | DGAT1 (0.51) | DGAT1KCNMA1GAAMGAMAMY1A | |
| SCHEMBL21904738 | 0.75 | DGAT1 (0.51) | DGAT1KCNMA1GAAMGAMAMY1A | |
| SCHEMBL2732055 | 0.73 | DGAT1 (0.49) | DGAT1KCNMA1GAAMGAMAMY1A | |
| SCHEMBL29031460 | 0.73 | DGAT1 (0.49) | DGAT1KCNMA1GAAMGAMAMY1A | |
| SCHEMBL2732054 | 0.69 | DGAT1 (0.44) | DGAT1KCNMA1GAAMGAMAMY1A | |
| SCHEMBL3893181 | 0.68 | DGAT1 (0.57) | DGAT1KCNMA1GAAMGAMAMY1A | |
| SCHEMBL21904737 | 0.68 | DGAT1 (0.49) | DGAT1KCNMA1GAAMGAMAMY1A | |
| SCHEMBL2732640 | 0.67 | DGAT1 (1.00) | DGAT1KCNMA1GAAMGAMAMY1A | |
| SCHEMBL3868690 | 0.67 | SLC9A1 (0.40) | DGAT1KCNMA1GAAMGAMAMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023141693-A1 | SYNTHETIC GLYCOLIPIDS AND GLYCOLIPOSOME COMPOSITIONS SUITABLE FOR CARGO DELIVERY TO THE CENTRAL NERVOUS SYSTEM | KORANEX CAPITAL (CA) | 2023-08-03 | — | — | WO | claimed |
| US-20240158402-A1 | METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240124449-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS, INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-11866440-B2 | Methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-09 | — | — | US | disclosed |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | NOVITA PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2023141693-A1 | SYNTHETIC GLYCOLIPIDS AND GLYCOLIPOSOME COMPOSITIONS SUITABLE FOR CARGO DELIVERY TO THE CENTRAL NERVOUS SYSTEM | KORANEX CAPITAL (CA) | 2023-08-03 | — | — | WO | disclosed |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | CORNELL UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230057246-A1 | NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR | LAURUS LABS LIMITED (IN) | 2023-02-23 | — | — | US | disclosed |
| US-11235316-B2 | Catalysts for chemical reactions in a water-surfactant mixture | NOVARTIS AG (CH) | 2022-02-01 | — | — | US | disclosed |
| EP-1585758-A4 | PEPTIDES HAVING PROTECTED AMINES OF UNTARGETED SITES, METHODS FOR PRODUCTION THEREOF AND OF SPECIFICALLY CONJUGATED PEG PEPTIDES USING THE SAME | PEGSPHERE CO LTD (KR) | 2006-06-07 | — | — | EP | disclosed |
| EP-1654280-A2 | PREPARATION OF SOMATOSTATIN PEPTIDES | Novartis AG (CH) | 2006-05-10 | — | — | EP | disclosed |
| US-20060063914-A1 | specifically conjugating polyethylene glycol to targeted sites of the synthetic peptides; pegylation; synthetic peptides having selectively protected amines of untargeted sites | PEGSPHERE CO., LTD. (KR) | 2006-03-23 | — | — | US | disclosed |
| WO-2005116643-A2 | IDENTIFICATION OF COMPOUNDS MODIFYING A CELLULAR RESPONSE | CARLSBERG A/S (DK) | 2005-12-08 | — | — | WO | disclosed |
| EP-1585758-A1 | PEPTIDES HAVING PROTECTED AMINES OF UNTARGETED SITES, METHODS FOR PRODUCTION THEREOF AND OF SPECIFICALLY CONJUGATED PEG PEPTIDES USING THE SAME | PEGSPHERE Co., Ltd. (KR) | 2005-10-19 | — | — | EP | disclosed |
| WO-2005014624-A2 | PREPARATION OF SOMATOSTATIN PEPTIDES | NOVARTIS AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| US-6828392-B2 | For use as solid supports for organic synthesis, for enzymatic assays, for immobilization of biomolecules, for controlled release of drugs, and for chromatographic separations | CARLSBERG A/S (DK) | 2004-12-07 | — | — | US | disclosed |
| WO-2004065412-A1 | PEPTIDES HAVING PROTECTED AMINES OF UNTARGETED SITES, METHODS FOR PRODUCTION THEREOF AND OF SPECIFICALLY CONJUGATED PEG PEPTIDES USING THE SAME | PEGSPHERE CO., LTD. (KR) | 2004-08-05 | — | — | WO | disclosed |
| US-20030096918-A1 | Hydroxy and amine functionalised resins | CARLSBERG A/S (DK) | 2003-05-22 | — | — | US | disclosed |
| US-20030027982-A1 | Method for inverse solid phase synthesis of peptides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158402-A1 | METHODS FOR INHIBITING FASCIN | FSCN1, NLN, TNNI3 | DGAT1 1790/4885KCNMA1 2183/4885GAA 577/4885 |
| US-11235316-B2 | Catalysts for chemical reactions in a water-surfactant mixture | LSS, DCXR, CEL | DGAT1 148/4885KCNMA1 3777/4885GAA 920/4885 |
| US-20240124449-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | DGAT1 673/4885KCNMA1 3361/4885GAA 630/4885 |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | DGAT1 673/4885KCNMA1 3361/4885GAA 630/4885 |
| US-20230057246-A1 | NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR | CYP3A4, CYP4A11, CYP3A43 | DGAT1 1501/4885KCNMA1 3077/4885GAA 74/4885 |
| US-20230310378-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | MIF, CXCL10, CCL2 | DGAT1 2250/4885KCNMA1 4421/4885GAA 3948/4885 |
| US-11701342-B2 | Co-therapies including a metastasis inhibitor | MIF, CXCL10, CCL2 | DGAT1 2250/4885KCNMA1 4421/4885GAA 3948/4885 |
| US-20030027982-A1 | Method for inverse solid phase synthesis of peptides | SSU72, SUB1, NPPA | DGAT1 4534/4885KCNMA1 3515/4885GAA 3886/4885 |
| US-11866440-B2 | Methods for inhibiting fascin | FSCN1, NLN, TNNI3 | DGAT1 1790/4885KCNMA1 2183/4885GAA 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.